News
NBY
0.1109
-20.22%
-0.0281
NBY Stock Earnings: NovaBay Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023
NovaBay Pharmaceuticals reported earnings per share of -21 cents. The company reported revenue of $3.73 million. This was 9.62% better than the analyst estimate for revenue of -20 million. The stock was down 2.7% after the market closed.
Investorplace · 1d ago
NovaBay Pharmaceuticals: Q4 Earnings Insights
NovaBay Pharmaceuticals reported its Q4 earnings of $-0.21 on March 26. The company beat estimates by 30.0%. The company's revenue was up $84 thousand from the same period last year. NovaBay pharmaceuticals is expected to announce its earnings Tuesday.
Benzinga · 1d ago
NovaBay Pharmaceuticals Q4 EPS $(0.21) Beats $(0.30) Estimate, Sales $3.73M Beat $3.40M Estimate
NovaBay Pharmaceuticals reports quarterly losses of $0.21 per share. The company reported quarterly sales of $3.73 million which beat the analyst consensus estimate by 9.62%. The company also reported a 30 percent increase in sales from the same period last year.
Benzinga · 1d ago
*NovaBay 4Q Loss $4.11M >NBY
Dow Jones · 1d ago
Press Release: NovaBay Pharmaceuticals Reports -2-
(or the execution on capital raise opportunities) not being sufficient to meet the Company's cash needs. Other risks relating to NovaBay's business are detailed in the company's latest Form 10-K/Q filings with the Securities and Exchange Commission. The forward-looking statements in this release speak only as of the date of this release.
Dow Jones · 1d ago
*NovaBay 4Q Sales $3.73M >NBY
Dow Jones · 1d ago
Earnings Scheduled For March 26, 2024
Bluebird bio is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. AIM ImmunoTech is estimated to report earnings for its fourth quarter. Elbit Systems is projected to report. Quarterly earnings at $1.38 per share.
Benzinga · 2d ago
NovaBay Pharmaceuticals to Hold 2023 Fourth Quarter and Full Year Conference Call on March 26, 2024
NovaBay Pharmaceuticals, Inc. Will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024. The company will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Barchart · 2d ago
Weekly Report: what happened at NBY last week (0318-0322)?
Weekly Report · 2d ago
Weekly Report: what happened at NBY last week (0311-0315)?
Weekly Report · 03/18 12:21
Novabay Reported Preliminary Q4 2023 Sales Of $3.7M, Consisting Of $0.9M From Its DERMAdoctor Skincare Segment And $2.8M From Its Eyecare And Wound Care Segment Versus Consensus Of $3.4M
Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million. DERMAdoctor skincare segment loss includes a $2.7 million loss in the skincARE segment. The company expects to post a loss of $3 million in the quarter.
Benzinga · 03/14 12:06
*NovaBay Cash as of Dec 31 Was $3.1M >NBY
Dow Jones · 03/14 12:02
*NovaBay Expects to Close the Transaction Before the End of the 1Q of 2024 >NBY
Dow Jones · 03/14 12:02
*NovaBay To Sell Its DERMAdoctor Skincare Business Including All Pdt Inventory for $1M in Cash >NBY
Dow Jones · 03/14 12:02
Press Release: NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
NovaBay Pharmaceuticals to sell its DERMAdoctor skincare business for approximately $1.0 million in cash. The company expects to close the transaction before the end of the first quarter of 2024. The sale will reduce operating expenses and bolsters cash. NovaBay also announced an agreement to market Eyenovia's eye product.
Dow Jones · 03/14 12:00
*NovaBay Pharmaceuticals Announces Agreement to Sell Its DERMAdoctor Skincare Business Segment
Dow Jones · 03/14 12:00
Weekly Report: what happened at NBY last week (0304-0308)?
Weekly Report · 03/11 12:16
Weekly Report: what happened at NBY last week (0226-0301)?
Weekly Report · 03/04 12:20
Weekly Report: what happened at NBY last week (0219-0223)?
Weekly Report · 02/26 12:41
Weekly Report: what happened at NBY last week (0212-0216)?
Weekly Report · 02/19 12:43
More
Webull provides a variety of real-time NBY stock news. You can receive the latest news about Novabay Pharma through multiple platforms. This information may help you make smarter investment decisions.
About NBY
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company. The Company develops and sells scientifically created and clinically proven eyecare and skincare products. Its product, Avenova Antimicrobial Lid & Lash Solution is used for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution. Its trademarks include Avenova, CelleRx, PhaseOne, NeutroPhase, DERMAdoctor, Kakadu C, AINT Misbehavin, KP Duty, and depictions of Dr. Audrey Kunin. Avenova Spray has broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. The Company, through its subsidiary DERMAdoctor, LLC, offers approximately 30 dermatologist-developed products targeting common skin concerns, ranging from aging and blemishes to dry skin, perspiration, and keratosis pilaris.